Trial Profile
NEVO-III
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2009
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms NEVO-III
- Sponsors Cordis Corporation
- 07 Apr 2009 New trial record.